Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HilleVax, Inc.HLVX · Entity 75097 | CFO & Chief Business Officer | April 28, 2022 | April 28, 2022 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director | May 23, 2024 | May 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HilleVax, Inc.
Report date April 28, 2022 · Filed April 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 769,055 |
Reported balance
Holding disclosure · report date 2022-04-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 769,055 F1: Includes 425,175 shares of restricted stock subject to repurchase by the Issuer. F2: Consists of (i) 510,183 shares of common stock held in the David A. Socks 2013 Revocable Trust of which Mr. Socks is a trustee; and (ii) 258,872 shares of common stock held by family trusts for which Mr. Socks is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 425,175 shares of restricted stock subject to repurchase by the Issuer.
F2: Consists of (i) 510,183 shares of common stock held in the David A. Socks 2013 Revocable Trust of which Mr. Socks is a trustee; and (ii) 258,872 shares of common stock held by family trusts for which Mr. Socks is a trustee.
Phathom Pharmaceuticals, Inc.
Report date May 23, 2024 · Filed May 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,500 |
Reported balance
After 2024-05-23 transaction · row 1
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 10,500 · Balance 19,500 F1: The Restricted Stock Units ("RSUs") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2034-05-22 | Direct | 17,500 |
Reported balance
After 2024-05-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-23 · Grant · Disposed 17,500 · Balance 17,500 F2: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectDavid A. Socks Family Trust | 1,211,346 |
Reported balance
Holding disclosure · report date 2024-05-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,211,346 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 409.73 |
Reported balance
Holding disclosure · report date 2024-05-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 409.73 |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units ("RSUs") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2024 Filed May 24, 2024 19:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $10.30 | $0.00 |
DisclosureSEC source: 0000950170-24-064810 · ownership.xml · derivative · entry 4 Socks David A · CIK 0001378847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-05-22 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| May 23, 2024 Filed May 24, 2024 19:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-064810 · ownership.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| May 25, 2023 Filed May 30, 2023 18:57 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $11.72 | $0.00 |
DisclosureSEC source: 0001209191-23-033020 · doc4.xml · derivative · entry 4 Socks David A · CIK 0001378847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-24 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 18:57 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033020 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:47 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001209191-22-032586 · doc4.xml · derivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-05-24 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| October 08, 2021 Filed Oct 8, 2021 18:28 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,529 | $32.05 | $81,051.92 |
DisclosureSEC source: 0001209191-21-060109 · doc4.xml · nonDerivative · entry 2 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,211,346 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.82 to $32.58. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 18:28 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 15,471 | $32.66 | $505,343.20 |
DisclosureSEC source: 0001209191-21-060109 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,213,875 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $33.16. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 20:37 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 4,100 | $32.06 | $131,446.00 |
DisclosureSEC source: 0001209191-21-057517 · doc4.xml · nonDerivative · entry 3 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,229,346 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.66 to $32.57. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 20:37 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 324 | $33.31 | $10,791.08 |
DisclosureSEC source: 0001209191-21-057517 · doc4.xml · nonDerivative · entry 2 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,233,446 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.36. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 20:37 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 13,576 | $32.79 | $445,113.60 |
DisclosureSEC source: 0001209191-21-057517 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,233,770 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.20 to $33.1650. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 17:31 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 13,791 | $31.49 | $434,288.24 |
DisclosureSEC source: 0001209191-21-052287 · doc4.xml · nonDerivative · entry 2 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,247,346 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.80.The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 17:31 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 4,209 | $30.47 | $128,249.91 |
DisclosureSEC source: 0001209191-21-052287 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,261,137 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.98. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The total number of outstanding shares reflects an increase of 4,401 shares to correct an arithmetic error in the total number of shares initially reported on his Form 4 filed on November 9, 2020. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 20:43 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 13,960 | $34.00 | $474,656.75 |
DisclosureSEC source: 0001209191-21-043851 · doc4.xml · nonDerivative · entry 3 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,260,945 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.85 to $34.77. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 20:43 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 156 | $35.09 | $5,473.56 |
DisclosureSEC source: 0001209191-21-043851 · doc4.xml · nonDerivative · entry 2 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,274,905 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.86 to $35.21. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 20:43 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 25,884 | $34.07 | $881,810.94 |
DisclosureSEC source: 0001209191-21-043851 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,275,061 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.85 to $34.83. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2021 Filed May 24, 2021 17:35 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $35.49 | $0.00 |
DisclosureSEC source: 0001209191-21-035466 · doc4.xml · derivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-05-20 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document |
| May 20, 2021 Filed May 21, 2021 18:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 305 | $35.27 | $10,756.19 |
DisclosureSEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 6 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,300,945 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.23 to $35.41. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 20, 2021 Filed May 21, 2021 18:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,278 | $34.93 | $79,579.65 |
DisclosureSEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 5 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,301,250 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.23 to $35.20. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 20, 2021 Filed May 21, 2021 18:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 899 | $33.76 | $30,350.78 |
DisclosureSEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 4 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,303,528 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.20 to $34.18. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 21, 2021 18:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 3,229 | $33.38 | $107,782.73 |
DisclosureSEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 3 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,304,427 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.32 to $33.49. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 21, 2021 18:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 16,020 | $32.78 | $525,193.27 |
DisclosureSEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 2 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,307,656 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.30 to $33.28. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 21, 2021 18:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 17,269 | $31.96 | $551,842.98 |
DisclosureSEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,323,676 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.29 to $32.28. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 16:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 6,795 | $38.03 | $258,415.21 |
DisclosureSEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 7 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,340,945 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.74 to $38.35. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 16:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 6,328 | $37.37 | $236,501.41 |
DisclosureSEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 6 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,347,740 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.74 to $37.73. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 16:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 3,359 | $35.97 | $120,822.56 |
DisclosureSEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 5 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,354,068 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.65 to $36.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2021 Filed Apr 7, 2021 16:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,400 | $34.96 | $48,944.70 |
DisclosureSEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 4 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,357,427 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.37. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 16:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,730 | $37.15 | $64,275.04 |
DisclosureSEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 3 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,358,827 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.02 to $37.59. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 16:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 7,769 | $36.40 | $282,793.15 |
DisclosureSEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 2 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,360,557 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.02 to $37.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 16:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 12,619 | $35.69 | $450,336.78 |
DisclosureSEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,368,326 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.02 to $36.01. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2021 Filed Mar 12, 2021 17:54 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 500 | $46.67 | $23,335.00 |
DisclosureSEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 6 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,380,945 Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 17:54 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 731 | $47.54 | $34,749.33 |
DisclosureSEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 5 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,381,445 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $47.67. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 17:54 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 41,698 | $47.18 | $1,967,349.17 |
DisclosureSEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 4 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,382,176 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.50 to $47.49. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 17:54 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,802 | $49.93 | $89,974.40 |
DisclosureSEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 3 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,423,874 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.57 to $50.29. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 17:54 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 7,844 | $49.02 | $384,515.23 |
DisclosureSEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 2 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,425,676 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.53 to $47.50. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 17:54 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,425 | $48.32 | $117,167.03 |
DisclosureSEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,433,520 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.53 to $48.52. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2021 Filed Feb 23, 2021 18:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,084 | $44.70 | $93,147.92 |
DisclosureSEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 9 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,435,945 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.05 to $45.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2021 Filed Feb 23, 2021 18:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,881 | $43.35 | $81,534.01 |
DisclosureSEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 8 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,438,029 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.90. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2021 Filed Feb 23, 2021 18:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,019 | $42.50 | $43,309.33 |
DisclosureSEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 7 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,439,910 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.94. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 18:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,417 | $46.99 | $66,584.97 |
DisclosureSEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 6 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,440,929 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.81 to $47.35. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 18:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 7,241 | $46.03 | $333,267.03 |
DisclosureSEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 5 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,442,346 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.80 to $46.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 18:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 11,482 | $45.27 | $519,735.03 |
DisclosureSEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 4 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,449,587 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.76 to $45.755. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 18,316 | $47.61 | $872,024.76 |
DisclosureSEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 3 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,461,069 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.26 to $48.22. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 21,360 | $47.08 | $1,005,701.42 |
DisclosureSEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 2 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,479,385 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.26 to $47.25. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:14 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 5,200 | $46.02 | $239,307.64 |
DisclosureSEC source: 0001209191-21-013373 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,500,745 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.26 to $46.24. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 17:07 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 20,091 | $36.18 | $726,982.79 |
DisclosureSEC source: 0001209191-21-003443 · doc4.xml · nonDerivative · entry 3 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,532,945 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.97 to $36.54. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 17:07 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 7,074 | $35.74 | $252,812.03 |
DisclosureSEC source: 0001209191-21-003443 · doc4.xml · nonDerivative · entry 2 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,553,036 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.97 to $35.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 17:07 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 12,835 | $34.92 | $448,243.12 |
DisclosureSEC source: 0001209191-21-003443 · doc4.xml · nonDerivative · entry 1 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,560,110 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.48 to $35.32. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 20:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 100 | $42.00 | $4,200.00 |
DisclosureSEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 7 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,572,945 Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 20:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 12,915 | $41.43 | $535,071.03 |
DisclosureSEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 6 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,573,045 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.98. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 20:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 35,197 | $40.49 | $1,425,105.41 |
DisclosureSEC source: 0001209191-20-064565 · doc4.xml · nonDerivative · entry 5 Socks David A · CIK 0001378847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David A. Socks 2013 Revocable Trust Disclosed balance after: 1,585,960 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.